Metastasis to lymph nodes (LNs) is the most important factor in predicting cancer spread to distant organs in many types of tumors, including breast cancer and melanoma 1 . However, the mechanism by which the tumor modifies the draining LN to facilitate metastasis is poorly understood. Subcutaneous implantation of B16-F10 melanoma cells in the rear footpad of mice induces hypertrophy of the draining popliteal LN, which precedes and predicts melanoma metastasis 2, 3 . The tumor-draining LN (TDLN) demonstrates increased lymphocyte cellularity with an 8-and 3-fold accumulation of B and T cells, respectively. This lymphocyte accumulation is associated with extensive growth of the lymphatic sinuses (lymphangiogenesis) and a 20-fold increase in lymph flow through the TDLN compared to the non-TDLN (NTDLN) 2 . Moreover, enforced B cell accumulation in LNs of preneoplastic Eμ -c-myc mice drives LN lymphangiogenesis and accelerates melanoma metastasis 3 . In contrast, melanoma-bearing B cell-deficient μ MT mice fail to develop LN lymphangiogenesis 2 and show reduced tumor growth 4 . Taken together, these findings suggest that tumors signal to LNs to induce B cell accumulation and inhibit anti-tumor immune responses. Alternatively, tumors could signal via the bloodstream to induce systemic immune responses in the spleen and non-draining LNs, as well as in the TDLN.
or breast carcinoma cells implanted in the flank 5, [8] [9] [10] . Bregs exert an immunosuppressive effect in autoimmune disease by secreting IL-10 6, 7 or by promoting the generation of immunosuppressive regulatory T cells (Tregs) in cancer 8 . Bregs represent a heterogeneous population, and several different subtypes have been identified depending on the particular model studied 11 . B10 (CD1d , and peritoneal B-1a Bregs can produce IL-10 to suppress autoimmune disease 6, 7 . Adoptive transfer of tumor-evoked Bregs (tBregs B220 + CD25 + ) produced ex-vivo by culturing B cell with tumor conditioned media produce TGF-β to generate Tregs 8 which promote metastasis. In the present study, we identify the preferential accumulation of a B cell subset with regulatory activity localized to the TDLN using the B16-F10 melanoma footpad model. These B cells appear to utilize an unconventional mechanism to promote tumor growth. . Flow cytometric analysis of these developmental populations in wild-type mice demonstrates that all three B cell populations are present in NTDLNs (Fig. 1a) and TDLNs (Fig. 1b) . The MZ B cells represent a small proportion of LN B cells even though they are abundant in the spleen (Fig. 1c) . All three subsets are significantly increased in number in TDLNs (Fig. 1d) . However, the LN T2-MZP B cell subset shows the greatest preferential accumulation (2.4-fold) with a smaller increase in the frequency of Fo B cells, and no change in the proportion of MZ B cells in the TDLN (Fig. 1e ). These findings demonstrate the preferential accumulation of B220 + CD23 + T2-MZP and Fo populations, but not MZ B cells in the TDLN.
Results

Preferential accumulation of T2-MZP
Local accumulation of TDLN B cells. B cell alterations in TDLNs could reflect a local response
induced by lymphatic drainage to the LN, or the tumor could exert systemic effects via the bloodstream to induce lymphocyte accumulation in additional secondary lymphoid organs. To determine if lymphoid organs other than the TDLN exhibit B cell alterations in the footpad melanoma model, the uninvolved LNs and spleens from tumor-bearing mice were compared to tumor-free naïve littermates to detect any differences in B cell populations. NTDLNs and naïve popliteal LNs exhibited the same number of the three B cell populations (Fig. 2a) demonstrating that B cell accumulation is restricted to the TDLN, with the NTDLN resembling a naïve LN. Additionally, spleens from tumor-bearing and naïve mice showed similar numbers of each of the three B cell subtypes (Fig. 2b ). These findings demonstrate the absence of a significant systemic B cell response to the tumor, and they further indicate that the immune response is localized to the TDLN. . To determine if T2-MZP B cells possess regulatory activity in the footpad melanoma model, B cell-deficient μ MT littermates were reconstituted with 1 × 10 6 naïve splenic FACS-sorted B cell subsets at the time of tumor implantation, and tumor growth was measured over 21 days. LN B cells could not be used for these studies as they are L-selectin lo , so that they do not enter LNs efficiently 12, 13 . Mice receiving T2-MZP B cells grew significantly larger tumors compared to the vehicle control (Fig. 3a) Figure S1 ). These results demonstrate that only the T2-MZP B cell subset promotes tumor growth in μ MT mice.
T2-MZP
Since μ MT mice lack peripheral B cells, we sought to address whether adoptive transfer of T2-MZP B cells shows the same activity in wild-type mice with an intact B cell compartment. We hypothesized that the introduction of T2-MZP B cells should also accelerate tumor growth in mice that have a normal immune system. Wild-type littermates were reconstituted with 1 × 10 6 FACS-sorted naïve B cell subsets (T2-MZP or Fo lo ) or vehicle at the time of tumor implantation. Mice reconstituted with T2-MZP B cells grew significantly larger tumors at 21 days compared to vehicle control, while the Fo lo transfer again had no effect on tumor growth (Fig. 3b) . These findings indicate that transfer of T2-MZP B cells but not other B cell subsets accelerates tumor growth in both μ MT and wild-type mice, demonstrating that T2-MZP B cells possess tumor-promoting activity.
Previous studies identified IL-10 as a key mediator of Breg function in autoimmune disease and cancer 11, 14 , while other studies have found that B cell derived IL-10 is not necessary to mediate immunosuppression 5, 8 . To determine if B cell-derived IL-10 is increased in the TDLN, LNs from tumor-bearing wild-type mice were collected, stimulated, stained, and analyzed by flow cytometry for intracellular IL-10 ( Fig. 3c) . There was no change in the frequency of IL-10-producing B cells in the TDLN (Fig. 3d) , and this proportion is consistent with what is seen in naïve mice of the same age 15 , suggesting that other mechanisms mediate the tumor-promoting activity of LN B cells.
TDLN T cell subsets accumulate coordinately.
The TDLN also exhibits increased T lymphocyte content 2 . To determine if CD4 or CD8 T cell subsets differentially accumulate, TDLN and NTDLN T cells were phenotyped by flow cytometry. Both CD4 and CD8 T cells increase 3-fold in the TDLN relative to the NTDLN (Fig. 4a) , and the CD4/CD8 ratio remains unchanged in the TDLN (Fig. 4b) , demonstrating that both T cell populations coordinately accumulate in the TDLN. T cell accumulation is restricted to the TDLN, as no difference in the number of either population is altered when comparing NTDLNs versus naïve nodes (Fig. 4c) , or spleens from tumor-bearing and naïve mice (Fig. 4d ). These findings demonstrate that the TDLN is the initial site of the T cell immune response to tumors.
Bregs could potentially exert their regulatory function by promoting the conversion of resting CD4 T cells to CD4 + Foxp3 + Tregs, as been shown with ex vivo generated Bregs 8 . LNs from tumor-bearing wild-type mice were analyzed to determine if the TDLN, which features more T2-MZP B cells, contains a greater proportion of Tregs. The flow cytometric profile (Fig. 4e) and frequency of CD4 
Foxp3
+ Tregs (Fig. 4f) are the same in the TDLN and NTDLN, indicating that T2-MZP accumulation does not induce Treg generation within the TDLN. The percentages observed in the NTDLN resemble the frequency seen in naïve mice of a similar age 16 . We also examined the effector T (Teff) cell to Treg ratio. A lower ratio in the TDLN compared to the NTDLN would indicate a shift of the anti-tumor immune response since Tregs can inhibit Teff recruitment 17 . No difference in this ratio was measured in the TDLN compared to the NTDLN (Supplemental Figure S2) suggesting that Tregs are not responsible for regulating the immunosuppressive environment within the TDLN. 
Discussion
While Bregs have previously been described in the spleen of mice with cancer or autoimmune diseases 6, 7 this is the first demonstration of a Breg population that preferentially accumulates in the TDLN. How these T2-MZP B cells accumulate in the TDLN remains unknown. These cells could arise from proliferation of existing B cells within the TDLN or they could be selectively trafficked to the TDLN from the spleen. Overall, however, B cell accumulation is limited to the TDLN, since no change in B lymphocyte number is detected in the spleen or NTDLN. The modest T cell accumulation is also restricted to the TDLN, while no alterations in particular T cell subsets were noted in either the NTDLN or spleen from tumor-bearing mice compared to naïve mice. These findings support the hypothesis that the early, pre-metastatic, tumor immune response is restricted to the TDLN. The absence of a systemic B or T lymphocyte response to these small (10-35 mm 2 ) tumors further indicates that immune alterations detected within the TDLN are the result of local signaling between the tumor and the draining lymph node. In this model, the immune response to the tumor is likely mediated by soluble material from the tumor or antigen-presenting cells entering the LN via the lymphatic drainage from the tumor to the popliteal LN 18 . These findings demonstrate that TDLNs are a specialized environment where the immune response to tumors first develops. Other studies of tumor immune responses in mouse flank models have identified systemic immune responses in the spleen and NTDLNs that were not detected in our footpad tumor Data are from at least three independent experiments with 6 to 9 mice per group for all experiments. Significance was determined using a two-way repeated measures ANOVA with Bonferroni's correction for tumor area measurements and a Wilcoxon signed-rank test for paired samples for IL-10 measurements. **p = 0.0005 and ***p < 0.0001 when comparing T2-MZP to saline vehicle control.
Scientific RepoRts | 5:12255 | DOi: 10.1038/srep12255 model 9, 10, 19, 20 . Indeed, the type of immune response generated could depend on factors such as tumor size, the anatomical location of tumor implantation, or the type of cancer involved 21 . A single introduction of naïve T2-MZP B cells, but not other B cell subsets, accelerates tumor growth in both μ MT and wild-type mice. We previously showed that B cells are not detectible in footpad tumors of wild-type mice 2 , suggesting that B cells act within the TDLN rather than in the tumor microenvironment. While the mechanism by which the introduction of such a small number of Bregs accelerates tumor growth remains to be determined, it likely involves amplification of the initiating B cell-derived signal. Further investigation is required to determine how the early TDLN immune alterations relate to the anti-tumor immune responses.
Our finding that TDLN B cells do not produce increased IL-10 is consistent with reports that Breg activity does not necessarily involve IL-10 5, 8 . While the percent of T2-MZP B cells increases almost 3-fold in the TDLN, the proportion of IL-10-producing B cells does not change, suggesting that IL-10 expression is not restricted to T2-MZP B cells. This further supports the conclusion that IL-10 is likely not the regulatory mechanism utilized by this subset. Instead, TDLN T2-MZP B cells could exert an immunosuppressive effect by inducing LN lymphangiogenesis, as TDLNs from wild-type mice demonstrate extensive LN lymphangiogenesis not seen in the NTDLN 2 Furthermore, lymphangiogenesis has been shown to be a B cell-dependent process. TDLNs from μ MT mice lacking B cells do not demonstrate the same degree of lymphatic sinus growth as their wild-type counterparts 2 . Other studies have provided evidence for a role for lymph node lymphatic endothelial cells in mediating tolerance by deleting antigen-specific T cells 22, 23 . Alternatively, B cells could prevent an anti-tumor immune response by producing antibodies. For example, low affinity antibodies binding to Fc receptors can result in the recruitment of pro-tumorigenic mast cells and macrophages to tumors 24 . However, the small number of naïve Bregs introduced in our studies would seem insufficient to generate much tumor-specific antibody during the 21-day interval tested. Finally, B cells can polarize macrophages to a type-2 state 25 , which could promote tumor growth 24 . The footpad melanoma model will be useful to investigate the mechanism by which TDLN B cells promote tumor growth, and whether this involves immune activation or suppression within the tumor microenvironment.
Taken together, these studies identify pre-metastatic, local immune responses to the tumor, which include the preferential accumulation of a TDLN-resident Breg population that could generate an immunosuppressed environment within the TDLN. Similar alterations could be involved in human cancer, as TDLNs from patients with various types of solid tumors also significantly accumulate B cells 26, 27 . An understanding of the mechanism by which TDLN T2-MZP Bregs promote tumor growth could inform the development of therapeutic strategies to permit a robust anti-tumor immune response.
Materials and Methods
Mouse Melanoma Model. C57BL/6J and μ MT mice from Jackson Laboratory (Bar Harbor, ME)
were housed in a specific pathogen-free facility. Animals were handled according to institutional guidelines. Five week-old male and female littermates were injected subcutaneously with B16-F10 melanoma in one hind footpad, and saline was introduced in the contralateral footpad Flow Cytometry Analysis. The following anti-mouse antibodies were purchased from BioLegend (San Diego, CA) unless otherwise specified: purified anti-CD16/32 (Tonbo, San Diego, CA), B220, CD23, IgM (eBiosciences, San Diego, CA), CD21/35, CD4, CD8, IL-10, and Foxp3.
Lymphocytes from spleen and lymph nodes of C57BL/6J mice were harvested 2 . Cells were incubated with purified anti-CD16/32 and surface stained then fixed. Intracellular staining was carried out using the BD Cyofix/Cytoperm TM kit following manufacturer's protocol. For IL-10 analysis, lymphocytes were harvested, stimulated for 5 hours with 50 ng/ml PMA and 500 ng/ml Ionomycin with GolgiStop (contains monensin) (BD, San Jose, CA) and stained 5 . Analysis was conducting using a BD LSRII or BD CantoII flow cytometer and FlowJo software (Tree Star Ashland, OR).
Adoptive Transfer of B Cell Subsets. Spleens harvested from 4-6 week old C57BL/6J mice were pooled, homogenized, and filtered through a 70 μ m cell strainer. Single-cell suspensions were depleted of erythrocytes, surface stained, and sorted into follicular (Fo), follicular low (Fo lo ), Transitional 2-marginal zone precursor (T2-MZP), and marginal zone (MZ) B cell subsets by a BD FACSAriaIII using gates drawn according to previous reports 6 . B cell subsets at 1 × 10 6 cells per 100 μ l in Hanks Balanced Salt Solution (HBSS) were transferred retro-orbitally into 4-5 week old μ MT or wild-type mice at the time of tumor implantation.
Statistics.
All experiments were repeated a minimum of three times with at least two mice per cohort.
Statistical analyses were performed using GraphPad Prism 6 and were carried out using a Mann-Whitney U test for unpaired samples, a Wilcoxon signed-rank test for paired samples, or a two-way repeated measures ANOVA with Bonferroni's correction for tumor area measurements. Normality was assessed using the Anderson Darling test, and a two-tailed analysis was carried out for all comparisons.
